Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34). Revenue for the quarter came in at $140 thousand.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue
• UBS Reiterates Buy Rating on Darden Restaurants (DRI) Ahead of Q1 Earnings